Immune Cell Therapy

From the fourth cancer treatment
to the core of cancer treatment

Surgery, radiation therapy and chemotherapy (anti-cancer drugs) are known as the three major cancer treatments. Thanks to medical research and development, these three major treatments have made great progress, but there is still a lot of pain associated with the treatment itself and its side effects. Cancer immunotherapy is now attracting attention as the ‘fourth cancer treatment’.
In fact, it is thought that cancer cells are constantly being generated in our bodies, even in healthy people. However, because there are also immune cells that attack cancer cells, we do not immediately become ill. It is often said that cancer occurs when the balance between cancer cells and immune cells is disrupted for various reasons, and the proliferation of cancer cells exceeds that of the immune cells.
Therefore, our “cancer immunotherapy” aims to suppress cancer cells by artificially increasing the number of immune cells that humans naturally possess and strengthening their function.
In cancer immunotherapy, we extract immune cells from the patient’s own blood, massively increase their numbers, activate them, strengthen their ability to attack, and then return them to the patient’s body. In other words, it is a treatment method that utilizes the “ability to heal oneself”. As we use the patient’s own cells, there are almost no side effects. In rare cases, there may be a fever or allergic symptoms, but the patient can receive treatment while maintaining their quality of life (QOL).

Immune cell therapy provided by Bioaccell

Cancer immunotherapy is an advanced treatment based on cutting-edge science, including cell engineering and molecular immunology. The blood contains various cells involved in the immune system, and each has a different function and role in relation to cancer.
In the same way that each person has a different face, cancer cells also have a wide range of characteristics. Immunotherapy can be used to provide “personalized medicine” tailored to the individual patient, based on these characteristics.

Activated autologous lymphocyte therapy
(αβT・NK)

This is a treatment method in which lymphocytes and NK cells are isolated from the blood of the patient, activated and multiplied, and then returned to the body to attack cancer cells.

Dendritic cell therapy
(cellular immunity induction type)

Dendritic cells (DC) are immune cells that teach T lymphocytes, which directly attack cancer cells in the body, the markers of cancer (cancer antigens) and give them instructions for attack.

Self-antigen-stimulated CTL therapy
(AKT-DC)

This is a treatment method that uses the lymph nodes removed during radical surgery for lung cancer to proliferate and activate lymphocytes, and strongly induces cytotoxic T lymphocytes.

RIKEN-NKT
(NKT cell targeted therapy)

This is a dendritic cell vaccine therapy that uses the NKT cell activation technology of RIKEN Immune Regenertive Medicene Inc. to specifically promote the activation of NKT cells in the body.

Bioaccell Inc.

Head Office

#301 Kyodaikatura Venture plaza,
1-36, Gryo Ohara, Nishikyo-ku,
Kyoto-shi, Kyoto 615-8245, Japan

Phone: +81 75 394 6410
Fax: +81 75 394 6411
Mail: info@bioaccell.com

Tokyo Office

BAC HOUSE 4-19-3,
Ebisu,Shibuya-ku,
Tokyo 150-0013, Japan

Phone: +81 3 5475 6430
Fax: +81 35421 3433
Mail: info@bioaccell.com

Language Switcher

US English

JP 日本語